Galmed Pharmaceuticals Ltd (GLMD)

Galmed Pharmaceuticals Ltd (GLMD) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 8, 2026: market cap $4.9M; returns 1 week +6.3%.

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on developing Aramchol (arachidyl amido cholanoic acid), a first-in-class, liver-targeted Stearoyl-CoA Desaturase 1 (SCD1) modulator. The company's economic model is pre-revenue, sustained by equity financing and strategic capital management.

Groups GLMD belongs to

• Biotechnology
• Recent Reverse Splits
• Israel Companies
• Clinical Stage
• Clinical Stage Biopharma
• Pharmaceuticals
• NASH
• Liver Disease
• Metabolic Disorders
• Israel
• Fibrosis
• Healthcare

GLMD financial model: income statement, cash flow and balance sheet